Technological innovation, the development of human capital and the expansion of infrastructure are essential for the growth of the pharmaceutical industry, a sector that contributes to increasing the country’s productivity and generating high value-added jobs, as well as boosting investment and promoting the competitiveness.
The pharmaceutical industry in Mexico represents the second drug market in Latin America (LatAm) and occupies twelfth position worldwide, being a benchmark in the production of drugs due to installed capacity according to reports from the National Institute of Statistics and Geography ( INEGI).
The INEGI recorded that there are three entities highlighted by the concentration of 62% of the facilities dedicated to the manufacture of medicines: Mexico City represents 32%, Jalisco concentrates 20% and the State of Mexico 10%.
From 2019 to 2020, pharmaceutical industry jobs in Mexico increased by 3.6%, accounting for a total of 79,000 jobs. An interesting fact, women occupied 46.5% of the positions, in the average of the economy they represent 41.3% of the positions and in the manufacturing segments they occupy 36.9%.
In this context, Grupo Collins inaugurated a new plant for the production of medicines with an investment of more than 30 million dollars and the generation of more than 250 new jobs.
The production plant called Farma III was built over a period of three years and has production lines for the manufacture of tablets by direct compression, tablets by granulation and capsule; the objective of increasing the production of oral solids.
Within the framework of the 56th Anniversary of the founding of Productos Farmacéuticos Collins, the Executive President of Grupo Collins, María Teresa Tirado Díaz, explained that the Company maintains sustained growth with the foundations of a well-organized family structure and accompanied by the best leadership who They promote the Corporate Governance model.
“Family companies in the Mexican pharmaceutical industry are a reference in operating models, but they face great challenges to strengthen their presence, so we must take advantage of the differentiators and the different competitive advantages of the market,” emphasized Tirado Díaz.
Grupo Collins is a family company, 100% Mexican and proudly from Guadalajara, founded by T. Baltazar Tirado Escamilla, which integrates a total of five companies: Productos Farmacéuticos Collins, Cultivos Naturales San Francisco, Salud Natural, Collins Veterinary Division and MH Mega Health.
The Group is made up of around 1,800 employees, a multidisciplinary team that operates a total of 6 production plants strategically located in the Guadalajara Metropolitan Area (ZMG), five of these plants manufacture medicines for human health and the remaining one is intended for the veterinary segment.
Currently, with the infrastructure and capacity installed in the plants, Grupo Collins produces more than 400 brands of products and has around 200 health records, managing to contribute to the comprehensive health of millions of families.
Finally, it is important to highlight that, in June 2022, the Federal Commission for the Protection against Sanitary Risks (Cofepris) granted the Farma III Plant the Sanitary License for the operation of this new strategic facility. Additionally, in the first quarter of 2023, a visit was also received to obtain Good Manufacturing Practices (GMP) Certification.
Sustainability Management
The report called ‘The drug market in Mexico: Challenges and opportunities’presented in 2021 by the Mexican Institute for Competitiveness, AC (IMCO), detailed that Mexico is one of the most attractive markets to invest in the pharmaceutical industry, derived from the constant strengthening of the regulatory framework and compliance with sustainability models.
Collins Group is strengthening its Sustainability Model, which integrates Social Responsibility. For 6 years, the company Productos Farmacéuticos Collins has maintained the Socially Responsible Company (ESR) Distinction awarded by the Mexican Center for Philanthropy (Cemefi) and the Alliance for Corporate Social Responsibility (AliaRSE) and is part of the Global Compact of the Organization of the United Nations (UN).
The multidisciplinary team that makes up Collins has achieved sustained growth by integrating and strengthening the concept of Social Responsibility, based on the social commitment of the founder, T. Baltazar Tirado Escamilla, as well as the development of the Values and the Code of Ethics.
In 2020, Collins was recognized by Tops México within the ranking of “The best Socially Responsible Companies in Mexico”, in the ‘Diamond’ category, a distinction that it maintained in 2021 and that during 2022 it endorsed in the ‘Platinum’ category. Currently, the companies Productos Farmacéuticos Collins and Salud Natural are part of the “Super Companies 2023”.
Currently, Cemefi’s ESR Distinction seeks to be aligned with the 17 Sustainable Development Goals (SDGs) and the United Nations Global Compact, the latter also linked to the Communication of Progress (CoP) classification. English), requirement to be distinguished among the more than 15,000 companies adhering to the Global Compact.
Collins Group has a great responsibility as a generator of a CSR culture with employees and their families. Social Responsibility in the Company is a work in constant development and social commitment for the formation of cultural meanings that generate a sense of belonging.